Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
Tanta University, Tanta, EL Gharbia, Egypt
Faculty of Pharmacy, Tanta University, Tanta, Egypt
Yale Cancer Center, New Haven, Connecticut, United States
Christiana Care Health System, Newark, Delaware, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Sanatorio Allende, Cordoba, Argentina
Fundacion CORI para la Investigacion y Prevencion del Cancer, La Rioja, Argentina
Centro Medico IPAM, Rosario, Argentina
Korea University Anam Hospital, Seoul, Korea, Republic of
yuangang Qiu, Hangzhou, Zhejiang, China
Peking University Third Hospital, Beijing, Beijing, China
Zhongshan Hospital, Shanghai, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.